Diagnostics Manufacturing During COVID-19


Fully Operational. No expected interruptions to product or service delivery.

SCHOTT MINIFAB is dedicated to maintaining safe, healthy, and productive operations during COVID-19.

As a result of our continuous effort to mitigate the effects of COVID-19 on business operations, we are pleased to confirm that there are no current or future interruptions expected to product or service delivery.


All SCHOTT MINIFAB sites operate under a COVID-Safe plan. Each plan is site-specific and incorporates:

Strict compliance with local government regulations and health orders;

Administrative measures;

Engineering and social distancing measures;

Hygiene and use of PPE;

Staff training, well-being, and communications programs.


SITE STATUS: Scoresby, Victoria, Australia

Our head office and manufacturing facility is fully operational.

Although local government “Stage 4” restrictions have affected some businesses in the region, SCHOTT MINIFAB has been exempted from such restrictions as a manufacturer of medical and pharmaceutical products.

Staff operating in Scoresby work on a mixture of on-site and work from home arrangements depending on their role.

Fully Operational

SITE STATUS: Jena, Germany

Our centre for glass excellence in Jena, Germany, is fully operational.

Staff operating in Jena work on a mixture of on-site and work from home arrangements depending on their role.

Fully Operational

SITE STATUS: San Francisco, USA

Our sales and project support activities in San Francisco, USA, are fully operational via a work-from-home model.

Fully Operational


Further Information: For further information on our COVID-Safe operations, please contact us.

Latest News from Minifab

Greg Wolters, CEO of SCHOTT MINIFAB with the 20 Millionth TearLab Osmolarity Test Card prior to shipping.
July 29, 2020

TearLab and SCHOTT MINIFAB Announce '20 Million' Manufacturing Milestone

in News
TearLab® Corporation, together with SCHOTT MINIFAB are celebrating an important milestone with the delivery of the 20 millionth microfluidic eye test card from the production line in Melbourne, Australia. The milestone comes as a result of a 13-year contract manufacturing partnership between the two companies, beginning in 2007 with an ambitious microfluidic product development program. READ MORE
June 22, 2020

Microfluidic product development: Guiding principles to de-risk your development program

in Microfluidics
When it comes to managing and mitigating product development risk, there are six guiding principles that are proven to work. READ MORE
June 08, 2020


in News
Market leader in microfluidic device manufacture has re-branded from MINIFAB to SCHOTT MINIFAB. The change of name and visual re-brand comes after SCHOTT AG acquired the company in July 2019 and forms one part of an ongoing integration process. READ MORE
May 08, 2020

Point of care diagnostic manufacturing. Three key ways to reduce the cost of goods.

in Microfluidics
Taking a long-term view at the outset of the cartridge development program is critical for reducing the cost of goods (COGS) when the time inevitably comes to ramp up manufacturing volume. READ MORE

Subscribe for email updates

Stay up to date with the latest news, case studies and annoucements from Minifab.